Both thapsigargin- and tunicamycin-induced endoplasmic reticulum stress increases expression of Hrd1 in IRE1-dependent fashion

Neurol Res. 2019 Feb;41(2):177-188. doi: 10.1080/01616412.2018.1547856. Epub 2018 Nov 26.

Abstract

Objectives: We have investigated the impact of endoplasmic reticulum (ER) stress, which is often implicated in neurodegenerative diseases, on the expression of Hrd1, an E3 ubiquitin ligase that plays a central role in the process of ER-associated degradation (ERAD).

Methods: SH-SY5Y neuroblastoma cells, a frequently used model for studying neurotoxicity in dopaminergic neurons and the mechanisms of neurodegeneration associated with Parkinson's disease, and parental SK-N-SH cells were studied.

Results: We demonstrate that ER stress, induced by thapsigargin or tunicamycin, correlates with the increased expression of Hrd1 in both SH-SY5Y and SK-N-SH cells. Inhibition of PERK does not significantly suppress the thapsigargin- or tunicamycin-induced expression of Hrd1. Nevertheless, PERK inhibition has a positive effect on the survival of SH-SY5Y cells treated with thapsigargin but not on those treated with tunicamycin. Inhibition of IRE1 associated with the inhibition of XBP1 splicing does not affect the survival of SH-SY5Y cells treated with either thapsigargin or tunicamycin but results in the complete suppression of both the thapsigargin- and tunicamycin-induced expression of Hrd1.

Discussion: Thus, the ER-stress-induced expression of Hrd1 in SH-SY5Y depends on Hrd1 transcription activation, which is a consequence of IRE1 but not of PERK activation.

Keywords: Endoplasmic reticulum; Hrd1; Parkinson’s disease (PD); neurodegeneration; thapsigargin; tunicamycin.

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • Cell Line, Tumor
  • Endoplasmic Reticulum Stress / drug effects*
  • Endoribonucleases / metabolism*
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Neurodegenerative Diseases / metabolism*
  • Protein Serine-Threonine Kinases / metabolism*
  • Thapsigargin / pharmacology*
  • Tunicamycin / pharmacology*
  • Ubiquitin-Protein Ligases / metabolism*
  • eIF-2 Kinase / metabolism*

Substances

  • Anti-Infective Agents
  • Enzyme Inhibitors
  • Tunicamycin
  • Thapsigargin
  • SYVN1 protein, human
  • Ubiquitin-Protein Ligases
  • ERN1 protein, human
  • PERK kinase
  • Protein Serine-Threonine Kinases
  • eIF-2 Kinase
  • Endoribonucleases